Evidence map›Paper›PMID 35294578›Full record

ArticleDiabetologia2022

Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase.

Marie-Sophie Nguyen-Tu, Joseph Harris, Aida Martinez-Sanchez, Pauline Chabosseau, Ming Hu, Eleni Georgiadou, Alice Pollard, Pablo Otero, Livia Lopez-Noriega, Isabelle Leclerc and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 5 countries.

Marie-Sophie Nguyen-TuSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Joseph HarrisSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Aida Martinez-SanchezSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Pauline ChabosseauSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Ming HuSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Eleni GeorgiadouSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Alice PollardMRC- London Institute of Medical Sciences, Imperial College London, London, UK.
Pablo OteroSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Livia Lopez-NoriegaSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Isabelle LeclercSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Kei SakamotoNovo Nordisk Center for Basic Metabolic Research, Copenhagen, Denmark.
Dieter SchmollSanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
David M SmithEmerging Innovations Unit, Discovery Sciences, AstraZeneca R&D , Cambridge, UK.
David CarlingMRC- London Institute of Medical Sciences, Imperial College London, London, UK.
Guy A RutterSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. g.rutter@imperial.ac.uk.ORCID 0000-0001-6360-0343
Imperial College London · GBAstraZeneca (United Kingdom) · GBMRC London Institute of Medical Sciences · GBNanyang Technological University · SGNovo Nordisk (Denmark) · DKSanofi (Germany) · DE

Funding

Medical Research Council G0301081Medical Research Council MC_U120027537Medical Research Council MR/P023223/1Medical Research Council MR/R022259/1Wellcome Trust WT212625/Z/18/Z
6 · The paper itself

Abstract

aims/hypothesisAlthough targeted in extrapancreatic tissues by several drugs used to treat type 2 diabetes, the role of AMP-activated protein kinase (AMPK) in the control of insulin secretion is still debatable. Previous studies have used pharmacological activators of limited selectivity and specificity, and none has examined in primary pancreatic beta cells the actions of the latest generation of highly potent and specific activators that act via the allosteric drug and metabolite (ADaM) site.

methodsAMPK was activated acutely in islets isolated from C57BL6/J mice, and in an EndoC-βH3 cell line, using three structurally distinct ADaM site activators (991, PF-06409577 and RA089), with varying selectivity for β1- vs β2-containing complexes. Mouse lines expressing a gain-of-function mutation in the γ1 AMPK subunit (D316a) were generated to examine the effects of chronic AMPK stimulation in the whole body, or selectively in the beta cell.

resultsAcute (1.5 h) treatment of wild-type mouse islets with 991, PF-06409577 or RA089 robustly stimulated insulin secretion at high glucose concentrations (p<0.01, p<0.05 and p<0.001, respectively), despite a lowering of glucose-induced intracellular free Ca CONCLUSIONS/

interpretationAMPK activation exerts complex, time-dependent effects on insulin secretion. These observations should inform the design and future clinical use of AMPK modulators.

Indexed as

Diabetes Mellitus, Type 2Insulin-Secreting CellsAMP-Activated Protein KinasesAnimalsGlucoseInsulinInsulin SecretionMiceAMP-Activated Protein KinasesGlucoseInsulin991AMP-activated protein kinaseAMPKATP/ADPBeta cellCa2 +Insulin secretionLKB1PF-06409577RA089Type 2 diabetes

Identifiers

PMID35294578
PMCPMC9076735
OpenAlexW4221078024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.